L&T-TECHNOLOGY-SERVICES
16.9.2020 09:32:21 CEST | Business Wire | Press release
Exponential-e, a UK-based leading & innovative CSP of enterprise connectivity & unified communications services, today entered into a strategic partnership with L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global pure-play engineering services company, to jointly offer workplace transformation solutions to customers working in the post-COVID environment.
In the “new normal” brought on by the pandemic, enterprises are ramping up operations in phases and planning to bring back their workforce, with their health and safety being the top priority. During these times, the need of the hour for companies is to retrofit the workplace with safety solutions on a fully digital foundation that can scale to intelligent buildings/campuses, smart facilities and offices.
According to the partnership, LTTS will offer its latest solution i-BEMS™ Shield , built on the company’s award-winning i-BEMS™ framework, and anchored on Exponential-e’s next-gen composite SDN carrier grade network & cloud infrastructure. The combination of these solutions will accelerate digital transformation of the workplace, across industries through digital technologies and platforms.
LTTS’ Intelligent Building Experience Management System, i-BEMS™ is a modular ‘system-of-systems’ platform that unifies all campus operations under one system and focuses on creating digital experiences and building optimization.
To build future-facing workplaces, i-BEMS™ is deploying Shield , a module within the solution that automates and develops smart systems and provides real-time insights to diagnose inefficiencies for quick decision making. i-BEMS™ Shield’s advanced digital interface redefines contactless interaction and surveillance by enabling temperature detection, face detection and tracking, air quality management, occupancy management and energy management.
Exponential-e, a leader in delivering fast, low latency connectivity, flexible and resilient Cloud solutions and world class IT services, will provide the platform for i-BEMS™ Shield to scale new heights of safety at workspace. The company’s ‘Software Defined-Digital Platform’, anchored on world class SD-WAN hosting the LTTS full stack digital innovation applications has the potential to spawn an ecosystem powered by digital VAS; drones-as-a service, connected cars, video-analytics as a service, AR/VR, gaming, smart cities & intelligent buildings are high in impact & value. Every industry is transforming itself through mobility & digital technologies. The LTTS-Exponential-e partnership accelerates the transformation by enabling a platform-based business federated in structure for companies across industries to collaborate and co-create new markets and revenue generating services.
Lee Wade, Founder & CEO, Exponential-e said , “The needs of businesses in the post-COVID environment is set for a dramatic change. While green quotient and sustainability were focus areas earlier for adopting smart building frameworks for campuses, enterprises now are faced with the urgent need of ensuring a safe and secured workplace environment for their workforces. With increasing customer engagement devices being used to help the modern-day work environment, we provide a software-defined network where functions can be deployed seamlessly. We are pleased to partner with an engineering services leader like LTTS and are confident that together, we will co-develop a value proposition that aligns with the present day needs of businesses in this ‘new normal’ world.”
Gaurav Gupta, Chief Business Officer, Europe, at L&T Technology Services said , “Worldwide the most evident trend to emerge as a fallout of COVID-19 are the disruptive innovations driven by new-age digital technologies. The role of ER&D services in shaping such cutting-edge innovative solutions will only grow. Our strategic partnership with Exponential-e is one such initiative that promises to redefine the smart building ecosystem and we are glad to be the pioneers on this front along with Exponential. This tie-up will lay the foundation for multiple industry leading initiatives on smart and secure workspaces and campuses in the near future.”
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a publicly listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 53 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 16,600 employees spread across 17 global design centers, 28 global sales offices and 51 innovation labs as of June 30, 2020. For more information, visit https://www.ltts.com/
About Exponential‐e
Exponential-e is a Cloud, Connectivity and Communications pioneer with a difference. From launching the world’s first Virtual private LAN in 2006 on its privately-owned 100GigE secure and super-fast Network, to its recent launch of its Software-Defined Digital Platform (SD-DP). (https://www.exponential-e.com/solutions/digital-transformation-model ).
Exponential-e’s commitment to innovation has resulted in it being recognised as one of the fastest-growing private companies in the UK. Exponential-e has also built an extensive solutions portfolio, enabling the creation of services tailored specifically to its customers’ operational needs – whether that be for Private & Public Cloud, Data Centre, Unified Communications, Cyber Security or managed IT Services.
Delivering customer service excellence is at the heart of Exponential-e. That’s why it’s trusted by over 3,000 customers, with 96% reference-ability and an industry-leading Net Promoter Score of 73.
We work to international management standards and are accredited with 8 ISO accreditations. Today, Exponential-e employs 700 staff members across London, Manchester and Chippenham.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005140/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom